# Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

> **NCT04887935** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 24 (estimated)

## Conditions studied

- Prostate Cancer
- Cancer of Prostate

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT04887935
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-04
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04887935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04887935, "Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04887935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*